On August 17, 2026 AB Science S.A. (the "Company" or "AB Science," Euronext – FR0010557264 – AB) reported the successful settlement and delivery of the securities issued as part of its capital increases subscribed to by a limited number of investors and announced on August 10, 2026 (the "Private Placement").
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As announced on August 10, 2026, the Private Placement, totaling EUR 14.2 million (including the issuance premium and excluding the potential exercise of BSA-1 and BSA-2 warrants), was carried out through the issuance, without preemptive subscription rights and without a priority period, of:
(i) 3,606,560 new common shares of the Company (the "New Shares") issued at a price of EUR 0.61 per share, each accompanied by a stock subscription warrant (a "BSA-1") – five BSA-1s entitle their holder to subscribe for three new common shares of the Company at a price of EUR 1.00 per common share; and
(ii) 19,672,132 New Shares issued at a price of EUR 0.61 per share, each accompanied by a stock subscription warrant (a "BSA-2") – four BSA-2s entitle their holder to subscribe for seven new common shares of the Company at a price of EUR 1.00 per common share.
If all BSA-1s and BSA-2s are exercised, a total of 36,590,166 additional common shares of the Company will be issued, representing total additional proceeds of approximately EUR 36.6 million. Thus, taking into account the issuance of the New Shares and the potential future exercise of the BSA-1 and BSA-2 warrants, the total amount of the Private Placement will amount, if applicable, to approximately EUR 50.8 million.
On this basis, the ownership interest of a shareholder holding 1.00% of the Company’s share capital prior to the completion of the Private Placement and who did not subscribe to it is now 0.7747% on an undiluted basis and 0.6072% on a diluted basis prior to the exercise of the BSA-1 and BSA-2 warrants, and 0.5721% on a non-diluted basis and 0.5332% on a diluted basis after the exercise of BSA-1 and BSA-2 warrants.
Finally, it is confirmed that Stéphane Ledermann, the Company’s Chairman and Chief Executive Officer, participated in the Private Placement in the amount of EUR 150,000.
About masitinib
Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the course of central nervous system diseases.
About AB8939
AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications.
(Press release, AB Science, AUG 17, 2026, View Source [SID1234670174])